Dual Use of Medications (DUAL) Partnered Evaluation Initiative

药物双重用途 (DUAL) 合作评估计划

• 批准号: 10181835
• 负责人: Walid F. Gellad
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10181835
• 关键词: Academic Detailing; Address; Adoption; Adverse event; Agreement; Anticoagulants; Benzodiazepines; Calendar; Charge; Clinical; Clinical Pharmacists; Collaborations; Data; Data Analyses; Data Sources; Dose; Drug Interactions; Drug Targeting; Effectiveness; Elderly; Enrollment; Ensure; Evaluation; Focus Groups; Fostering; Funding; Future; Goals; Health; Health Insurance; Health Priorities; Health system; Healthcare Systems; Heart Diseases; Hypoglycemic Agents; Insurance Carriers; Insurance Coverage; Intervention; Interview; Learning; Malignant Neoplasms; Measurement; Medicare; Medication Systems; Mental disorders; Monitor; Opioid; Oral; Outcome; Outpatients; Patients; Pharmaceutical Preparations; Pharmacy Administration; Pharmacy facility; Physicians; Practical, Robust Implementation and Sustainability Model; Provider; Qualitative Methods; Randomized; Reach, Effectiveness, Adoption, Implementation, and Maintenance; Records; Research; Resources; Risk; Safety; Surveillance Program; System; Telephone Interviews; Time; United States Centers for Medicare and Medicaid Services; Variant; Veterans; Veterans Health Administration; Work; care coordination; clinical care; cost; dashboard; data integration; data sharing; design; effectiveness evaluation; effectiveness outcome; experience; health care service organization; high risk; implementation barriers; implementation facilitators; implementation outcomes; implementation science; improved; medication administration; medication safety; novel; novel therapeutics; opioid overdose; opioid use; opioid use disorder; pharmacy benefit; programs; tool

The VA Center for Medication Safety (VAMedSAFE) is charged with improving the safety of medication use for Veterans. VAMedSAFE’s interventions address the most serious, prevalent, and high-priority health conditions among Veterans, and yet they have a key limitation – they cannot account for medications received by Veterans outside VA. Over 80% of VA enrollees have access to medications through other forms of health insurance, including 50% with Medicare. There is strong evidence that receiving medications from multiple health systems poses serious health risks. The inability to integrate non-VA prescriptions into VA medication surveillance efforts has greatly diminished VA’s capacity to ensure safe prescribing to Veterans. Driven by this evidence, VA signed a groundbreaking agreement with the Centers for Medicare & Medicaid Services (CMS) to integrate CMS data on prescriptions filled by Veterans in Medicare into VAMedSAFE’s ongoing safety surveillance activities – something VA has never before been able to do. By the end of calendar year 2020, VAMedSAFE will have received and cleaned CMS data on dispensed Medicare prescriptions for all enrolled Veterans and will integrate these data into their ongoing medication surveillance activities. The objective of our proposed Dual Use of Medications (DUAL) Partnered Evaluation Initiative is to aid VAMedSAFE in developing and evaluating the roll-out of new quality enhancement tools using these combined CMS/VA data. Our evaluation has three aims, with the first aim split into two sub-aims. In Aim 1, we will work with VAMedSAFE to formatively evaluate the types of medications to prioritize when integrating CMS prescription data into their quality enhancement tools. Aim 1a will quantify how the integration of CMS prescription data could impact exposure measurement (e.g., number of patients identified as incident medication users) and outcomes (e.g., number of patients with a medication-related adverse event) for each ongoing VAMedSAFE surveillance program. Aim 1b will identify high-impact targets for new VA drug safety initiatives using CMS/VA data, using both quantitative and qualitative analyses. We will query the CMS/VA data to identify broad drug classes (e.g., hypoglycemics, opioids) that are frequently duplicated or overlapping between CMS and VA. Then, we will convene two interdisciplinary focus groups with key stakeholders to identify additional potential high-impact drug targets for future interventions using the CMS/VA data. In Aim 2, we will evaluate end users’ experiences with the first integration of CMS data into a VAMedSAFE drug safety dashboard focusing on direct-acting oral anticoagulant safety. Guided by the Practical, Robust Implementation and Sustainability Model (PRISM), we will conduct telephone interviews with end users of the dashboard (e.g., pharmacy directors, academic detailers, clinicians) to identify implementation barriers and facilitators and learn about their experiences receiving the data, how it impacts clinical care, and whether CMS data integration leads to unintended consequences. Finally, in Aim 3, we will partner with VAMedSAFE to design and deploy a stepped-wedge randomized evaluation of a 2nd drug safety dashboard using integrated CMS and VA data, using findings from Aims 1 and 2 to identify the optimal drug target and implementation support. We will use RE-AIM as a framework for examining effectiveness (e.g., drug discontinuation, adverse events) and implementation (e.g. reach, adoption) outcomes. These new data provide an unprecedented opportunity to strengthen VA medication safety surveillance for Veterans who receive medications through Medicare. This evaluation was requested and is co-funded by VAMedSAFE, which requires a non-research partnership, as the CMS/VA data can only be used for quality improvement. This project aligns with VA QUERI priorities to apply implementation science to real-world practices, use novel data sources for quality improvement, and help program offices build data capacity and evaluate new quality enhancement tools.

VA药物安全中心（VAMedSAFE）负责提高药物使用的安全性